{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:14:42Z","timestamp":1761894882470},"reference-count":36,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1016\/j.leukres.2009.01.040","type":"journal-article","created":{"date-parts":[[2009,3,24]],"date-time":"2009-03-24T08:18:07Z","timestamp":1237882687000},"page":"871-875","source":"Crossref","is-referenced-by-count":20,"title":["The metabolic consequences of imatinib mesylate: Changes on glucose, lypidic and bone metabolism"],"prefix":"10.1016","volume":"33","author":[{"given":"Massimo","family":"Breccia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuliana","family":"Alimena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 2","key":"10.1016\/j.leukres.2009.01.040_bib1","first-page":"37","article-title":"BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukaemia: using guidelines to make rational treatment choices","author":"Kantarjian","year":"2008","journal-title":"J Natl Compr Cnc Netw"},{"key":"10.1016\/j.leukres.2009.01.040_bib2","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1080\/10245330500234195","article-title":"Evolving molecular therapy for chronic myeloid leukaemia: are we on target?","volume":"10","author":"Copland","year":"2005","journal-title":"Hematology"},{"key":"10.1016\/j.leukres.2009.01.040_bib3","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s11864-006-0018-5","article-title":"Gastrointestinal stromal tumors: imatinib and beyond","volume":"7","author":"Schnadig","year":"2006","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.leukres.2009.01.040_bib4","doi-asserted-by":"crossref","first-page":"973","DOI":"10.4065\/81.7.973","article-title":"Chronic myeloid leukemia: diagnosis and treatment","volume":"81","author":"Quintas-Cardama","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.leukres.2009.01.040_bib5","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2009.01.040_bib6","first-page":"110","article-title":"IRIS 6-year follow-up: sustained survival and declining annual rate of transformation in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib","author":"Hochhaus","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2009.01.040_bib7","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Mechanisms of resistance to imatinib in chronic myeloid leukaemia (part I and II)","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.leukres.2009.01.040_bib8","doi-asserted-by":"crossref","first-page":"37747","DOI":"10.1074\/jbc.M105796200","article-title":"(STI571) influences metabolic enzyme activities and glucose carbon flow toward nucleic acid and fatty acid synthesis in myeloid tumor cells","volume":"276","author":"Boren","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.leukres.2009.01.040_bib9","doi-asserted-by":"crossref","first-page":"6661","DOI":"10.1158\/1078-0432.CCR-04-0039","article-title":"Imatinib (STI571) mediated changes in glucose metabolism in human leukemia BCR-ABL positive cells","volume":"10","author":"Gottschalk","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2009.01.040_bib10","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1038\/sj.onc.1208461","article-title":"Chronic myeloid leukaemia: an investigation into the role of BCR-ABL induced abnormalities in glucose transport regulation","volume":"24","author":"Barnes","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.leukres.2009.01.040_bib11","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0959-8049(03)00073-X","article-title":"18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec)","volume":"39","author":"Stroobants","year":"2003","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.leukres.2009.01.040_bib12","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0140-6736(04)17098-0","article-title":"Progression-free survival in gastrointestinal stromal tumors with high dose imatinib: randomised trial","volume":"364","author":"Verweji","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2009.01.040_bib13","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.1158\/0008-5472.CAN-05-3906","article-title":"Therapeutic effect of imatinib in gastrointestinal stromal tumors: AKT signalling dependent and independent mechanisms","volume":"66","author":"Tarn","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2009.01.040_bib14","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1200\/JCO.2004.04.217","article-title":"Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukaemia patients responsive to treatment","volume":"22","author":"Breccia","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2009.01.040_bib15","first-page":"ECR 21","article-title":"Reduction of glycosilated hemoglobin with stable insulin levels in a diabetic patient with chronic myeloid leukaemia responsive to imatinib","volume":"90","author":"Breccia","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2009.01.040_bib16","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1056\/NEJM200503103521023","article-title":"Imatinib and regression of type 2 diabetes","volume":"352","author":"Veneri","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2009.01.040_bib17","doi-asserted-by":"crossref","first-page":"126","DOI":"10.4158\/EP.13.2.126","article-title":"Imatinib and type 2 diabetes","volume":"13","author":"Dingli","year":"2007","journal-title":"Endocr Pract"},{"key":"10.1016\/j.leukres.2009.01.040_bib18","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1200\/JCO.2006.06.5318","article-title":"Non-islet-cell tumor induced hypoglycemia in patients with advanced gastrointestinal stromal tumor possibly worsened by imatinib","volume":"24","author":"Hamberg","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2009.01.040_bib19","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1007\/BF03347451","article-title":"Symptomatic hypoglycemia during imatinib mesylate in a non-diabetic female patient with gastrointestinal stromal tumor","volume":"30","author":"Haap","year":"2007","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.leukres.2009.01.040_bib20","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1096\/fj.06-6910com","article-title":"Amelioration of diabetes by imatinib mesylate (Gleevec): role of beta-cell NF-kappaB activation and anti-apoptotic preconditioning","volume":"21","author":"Hagerkvist","year":"2007","journal-title":"FASEB J"},{"key":"10.1016\/j.leukres.2009.01.040_bib21","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1042\/CS20070122","article-title":"Imatinib mesylate improves insulin sensitivity and glucose disposal rates in rats fed a high-fat diet","volume":"114","author":"Hagerkvist","year":"2008","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.leukres.2009.01.040_bib22","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1126\/science.1082095","article-title":"LRP: role in vascular wall integrity and protection from atherosclerosis","volume":"300","author":"Boucher","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.leukres.2009.01.040_bib23","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/j.leukres.2007.01.024","article-title":"Impaired fasting glucose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukaemia patients resistant to imatinib","volume":"31","author":"Breccia","year":"2007","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2009.01.040_bib24","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.leukres.2008.01.015","article-title":"Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukaemia patient unresponsive to imatinib and nilotinib","volume":"32","author":"Breccia","year":"2008","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2009.01.040_bib25","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1161\/01.ATV.0000128321.91782.b9","article-title":"Protective role of imatinib in atherosclerosis","volume":"24","author":"Kadowaki","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.leukres.2009.01.040_bib26","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1161\/01.ATV.0000124105.39900.db","article-title":"Imatinib attenuates diabetes-associated atherosclerosis","volume":"24","author":"Lassila","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.leukres.2009.01.040_bib27","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1161\/01.CIR.0000117234.08626.7C","article-title":"Oral imatinib mesylate (STI571\/gleevec) improves the efficacy of local intravascular endothelial growth factor-C gene transfer in reducing neointimal growth in hypercholesterolemic rabbits","volume":"109","author":"Leppanen","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.leukres.2009.01.040_bib28","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s10456-007-9080-2","article-title":"Anti-angiogenic effects of imatinib target smooth muscle cells but not endothelial cells","volume":"10","author":"Rocha","year":"2007","journal-title":"Angiogenesis"},{"key":"10.1016\/j.leukres.2009.01.040_bib29","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1056\/NEJMc052500","article-title":"Imatinib and hyperlipidemia","volume":"353","author":"Gottardi","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2009.01.040_bib30","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa051140","article-title":"Altered bone and mineral metabolism in patients receiving imatinib mesylate","volume":"354","author":"Berman","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2009.01.040_bib31","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/ajh.20778","article-title":"Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukaemia in late chronic phase, and this effects is associated with response","volume":"82","author":"Osorio","year":"2007","journal-title":"Am J Hematol"},{"key":"10.1016\/j.leukres.2009.01.040_bib32","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1056\/NEJMc062388","article-title":"Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism","volume":"355","author":"Grey","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2009.01.040_bib33","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1359\/jbmr.070719","article-title":"Imatinib promotes osteoblast differentiation by inhibiting PDGFR signalling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms","volume":"22","author":"O'Sullivan","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.leukres.2009.01.040_bib34","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.1182\/blood-2005-09-3568","article-title":"Imatinib as a potential antiresorptive therapy for bone disease","volume":"107","author":"Dewar","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2009.01.040_bib35","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejphar.2006.09.007","article-title":"Imatinib mesylate (Gleevec) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity","volume":"551","author":"El Hajj Dib","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.leukres.2009.01.040_bib36","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1182\/blood-2007-07-104281","article-title":"Long-term imatinib therapy promotes bone formation in CML patients","volume":"111","author":"Fitter","year":"2008","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212609000599?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212609000599?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,3]],"date-time":"2021-10-03T14:52:09Z","timestamp":1633272729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212609000599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["S0145212609000599"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2009.01.040","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2009,7]]}}}